Fact Sheet
IQVIA Use By Indication (UBI)
Indication split tracking and insights for the autoimmune biologics (AIB) market across European markets, for precise decision making and accelerating performance.
Feb 10, 2021
IQVIA Use by Indication (UBI) is a high precision, best of breed solution for tracking performance in the AIB market for EU4 (France, Germany, Italy, Spain) and Belgium, Ireland, Netherlands and United Kingdom. It delivers the most precise volume and value of AIB drug usage at indication and specialty level.
Market Intelligence Solutions
Powered by IQVIA's Information Offerings, our healthcare market intelligence solutions provides key summary data and actionable insights covering medicines and healthcare products in primary care, secondary care and supply chains across the UK, NHS and healthcare sectors.
You may also be interested in
Fact Sheet
Improving brand monitoring and sales force effectiveness in the UK hospital sector
IQVIA Hospital Pharmacy Audit (HPA)
Fact Sheet
IQVIA Core Data Sets
Delivered through intuitive modern tools and transformative technology, these solutions enable you to make informed decisions
Video
EMIS App Library by AppScript Promo Video to UK General Practitioners (GPs)
Enabling 58% of GPs in England to Recommend High Quality Digital Health Apps to Their Patients